Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl N Kraus

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Current Opinion in Microbiology|September 30, 2008
Low hanging fruit in infectious disease drug developmentCarl N Kraus
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 7, 2011
The safety record of fusidic acid in non-US markets: a focus on skin infectionsCarl N Kraus, Barry W Burnstead
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 12, 2005
Levofloxacin and macrolides for treatment of Legionnaires disease: multiple comparisons give few answersCarl N Kraus, Jyoti Zalkikar, John H Powers
Current Drug Safety|May 10, 2013
The practicing clinician and regulatory safety concernsR G McAllister, Timothy Franson, Carl N Kraus
Current Drug Safety|May 10, 2013
Improving the effect of FDA-mandated drug safety alerts with Internet-based continuing medical educationCarl N Kraus, Alan T Baldwin, R G McAllister
Antimicrobial Agents and Chemotherapy|February 19, 2015
Ambush of Clostridium difficile spores by ramoplanin: activity in an in vitro modelCarl N Kraus, Matthew W Lyerly, Robert J Carman
Molecules (Basel, Switzerland)|August 7, 2019
Efficacy of ARV-1502, a Proline-Rich Antimicrobial Peptide, in a Murine Model of Bacteremia Caused by Multi-Drug Resistant (MDR) <i>Acinetobacter baumannii</i>Yan Q Xiong, Liang Li, Yufeng Zhou, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium|August 13, 2008
CRAFT: Facilitating clinical trial execution qualityCarl N Kraus, Jean Rawlings, David R Anderson, et al.
Frontiers in Chemistry|December 5, 2019
Quantitation of a Novel Engineered Anti-infective Host Defense Peptide, ARV-1502: Pharmacokinetic Study of Different Doses in Rats and DogsAlexandra Brakel, Daniela Volke, Carl N Kraus, et al.
Frontiers in Chemistry|February 28, 2022
Functional Effects of ARV-1502 Analogs Against Bacterial Hsp70 and Implications for Antimicrobial ActivityAlexandra Brakel, Lisa Kolano, Carl N Kraus, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Current Opinion in Microbiology|September 30, 2008
Low hanging fruit in infectious disease drug developmentCarl N Kraus
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 7, 2011
The safety record of fusidic acid in non-US markets: a focus on skin infectionsCarl N Kraus, Barry W Burnstead
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 12, 2005
Levofloxacin and macrolides for treatment of Legionnaires disease: multiple comparisons give few answersCarl N Kraus, Jyoti Zalkikar, John H Powers
Current Drug Safety|May 10, 2013
The practicing clinician and regulatory safety concernsR G McAllister, Timothy Franson, Carl N Kraus
Current Drug Safety|May 10, 2013
Improving the effect of FDA-mandated drug safety alerts with Internet-based continuing medical educationCarl N Kraus, Alan T Baldwin, R G McAllister
Antimicrobial Agents and Chemotherapy|February 19, 2015
Ambush of Clostridium difficile spores by ramoplanin: activity in an in vitro modelCarl N Kraus, Matthew W Lyerly, Robert J Carman
Molecules (Basel, Switzerland)|August 7, 2019
Efficacy of ARV-1502, a Proline-Rich Antimicrobial Peptide, in a Murine Model of Bacteremia Caused by Multi-Drug Resistant (MDR) <i>Acinetobacter baumannii</i>Yan Q Xiong, Liang Li, Yufeng Zhou, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium|August 13, 2008
CRAFT: Facilitating clinical trial execution qualityCarl N Kraus, Jean Rawlings, David R Anderson, et al.
Frontiers in Chemistry|December 5, 2019
Quantitation of a Novel Engineered Anti-infective Host Defense Peptide, ARV-1502: Pharmacokinetic Study of Different Doses in Rats and DogsAlexandra Brakel, Daniela Volke, Carl N Kraus, et al.
Frontiers in Chemistry|February 28, 2022
Functional Effects of ARV-1502 Analogs Against Bacterial Hsp70 and Implications for Antimicrobial ActivityAlexandra Brakel, Lisa Kolano, Carl N Kraus, et al.
Pageof 2